3-bromo-6-hydroxyphenanthrene | 939034-60-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 3-bromo-6-hydroxyphenanthrene
• 英文别名: 6-bromophenanthren-3-ol；6-Bromophenanthren-3-ol
• CAS: 939034-60-3
• 化学式: C₁₄H₉BrO
• 分子量: 273.129
• InChiKey: LLZJIFQNFDSNIM-UHFFFAOYSA-N

物化性质

• 沸点：
  454.3±18.0 °C(Predicted)
• 密度：
  1.585±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-bromo-6-hydroxyphenanthrene 、 2-环丙基乙醇 在 偶氮二甲酸二叔丁酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 生成 3-bromo-6-(2-cyclopropylethoxy)phenanthrene
  参考文献：
  名称：

  WO2007/59610

  摘要：

  公开号：
• 作为产物：
  描述：

  3-溴-6-甲氧基菲 在 三溴化硼 、 水 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 3-bromo-6-hydroxyphenanthrene
  参考文献：
  名称：

  WO2007/59610

  摘要：

  公开号：

文献信息

• 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
  申请人：Chau Anh

  公开号：US20090075998A1

  公开（公告）日：2009-03-19

  The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

  该发明涵盖了式I的新化合物或其药学上可接受的盐。这些化合物是微粒体前列腺素E合酶-1（mPGES-1）酶的抑制剂，因此可用于治疗多种疾病或情况引起的疼痛和/或炎症，如骨关节炎，类风湿性关节炎和急性或慢性疼痛。还包括治疗由mPGES-1酶介导的疾病或情况的方法和制药组合物。
• 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
  申请人：Chau Anh

  公开号：US20070208017A1

  公开（公告）日：2007-09-06

  The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

  本发明涵盖了公式I的新化合物或其药学上可接受的盐。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此可用于治疗各种疾病或病况引起的疼痛和/或炎症，如骨关节炎、类风湿性关节炎和急性或慢性疼痛。还包括治疗由mPGES-1酶介导的疾病或病况的方法和制药组合物。
• Methods for Treating or Preventing Neoplasias
  申请人：Kargman Stacia

  公开号：US20090192158A1

  公开（公告）日：2009-07-30

  The present invention is directed to a method for treating or preventing a neoplasia in a human patient in need of such treatment comprising administering to the patient a compound that inhibits microsomal prostaglandin E synthase-1 in an amount that is effective for treating or preventing the neoplasia.

  本发明涉及一种治疗或预防人类患者肿瘤的方法，包括向患者施用一种抑制微粒体前列腺素E合酶-1的化合物，其剂量足以治疗或预防该肿瘤。
• WO2007/124589
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis of Chiral Helical 1,3-Oxazines
  作者：Harish R. Talele、Sibaprasad Sahoo、Ashutosh V. Bedekar

  DOI：10.1021/ol301267r

  日期：2012.6.15

  A series of novel 1,3-oxazines were prepared to construct a helical framework. The 1,3-oxazine attached to the phenanthrene unit showed a small bite angle theta (similar to 12 degrees), while the units attached to [4]helicene showed a larger theta (similar to 35 degrees) and exhibited helical isomers at ambient conditions. The diastereomers of the third type of helicene-like bis-oxazine attached to binaphthyl were easily separable and showed good thermal stability. All four diastereomers of bis-helicene were synthesized, and their absolute configuration was established.